Ayelet Grupper1,2, Nechama Sharon3,4, Talya Finn4,5, Regev Cohen4,5, Meital Israel6,7, Amir Agbaria4,7, Yoav Rechavi2,3, Idit F Schwartz1,2, Doron Schwartz1,2, Yonatan Lellouch4,8, Moshe Shashar9,4,7. 1. Nephrology Department, Tel Aviv Medical Center Tel Aviv, Tel Aviv, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Pediatric Hemato-Oncology Department, Laniado Hospital, Netanya, Israel. 4. Ruth and Bruce Rappoport Faculty of Medicine, Technion, Haifa, Israel. 5. Infectious Disease Unit, Laniado Hospital, Netanya, Israel. 6. Ruth and Bruce Rappoport Faculty of Medicine, Technion, Haifa, Israel msahashar@laniado.org.il. 7. Nephrology Section, Laniado Hospital, Netanya, Israel. 8. Clinical Laboratories Department, Laniado Hospital, Netanya, Israel. 9. Nephrology Department, Tel Aviv Medical Center Tel Aviv, Tel Aviv, Israel msahashar@laniado.org.il.
Abstract
BACKGROUND AND OBJECTIVES: Coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients on maintenance hemodialysis and the factors associated with it. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included 56 patients on maintenance hemodialysis (dialysis group) and a control group composed of 95 health care workers. All participants had received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine. The serology testing was done using Quant II IgG anti-Spike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay by Abbott a median of 30 days after receipt of the second dose of the vaccine. RESULTS: All subjects in the control group developed an antibody response compared with 96% (54 of 56) positive responders in the dialysis group. The IgG levels in the dialysis group (median, 2900; interquartile range, 1128-5651) were significantly lower than in the control group (median, 7401; interquartile range, 3687-15,471). A Mann-Whitney U test indicated that this difference was statistically significant (U=1238; P<0.001). There was a significant inverse correlation of age and IgG levels in both groups. The odds of being in the lower quartile were significantly higher for older individuals (odds ratio, 1.11 per year of age; 95% confidence interval, 1.08 to 1.20; P=0.004) and for the dialysis group compared with the control group (odds ratio, 2.7; 95% confidence interval, 1.13 to 7.51; P=0.05). Within the dialysis group, older age and lower lymphocyte count were associated with antibody response in the lower quartile (odds ratio, 1.22 per 1-year older; 95% confidence interval, 1.13 to 1.68; P=0.03 and odds ratio, 0.83 per 10-e3/µl-higher lymphocyte count; 95% confidence interval, 0.58 to 0.97; P=0.05). CONCLUSIONS: Although most patients on maintenance hemodialysis developed a substantial humoral response following the BNT162b2 vaccine, it was significantly lower than controls. Age was an important factor in the humoral response, regardless of chronic medical conditions.
BACKGROUND AND OBJECTIVES: Coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients on maintenance hemodialysis and the factors associated with it. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included 56 patients on maintenance hemodialysis (dialysis group) and a control group composed of 95 health care workers. All participants had received two doses of the BNT162b2 (Pfizer-BioNTech) vaccine. The serology testing was done using Quant II IgG anti-Spike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay by Abbott a median of 30 days after receipt of the second dose of the vaccine. RESULTS: All subjects in the control group developed an antibody response compared with 96% (54 of 56) positive responders in the dialysis group. The IgG levels in the dialysis group (median, 2900; interquartile range, 1128-5651) were significantly lower than in the control group (median, 7401; interquartile range, 3687-15,471). A Mann-Whitney U test indicated that this difference was statistically significant (U=1238; P<0.001). There was a significant inverse correlation of age and IgG levels in both groups. The odds of being in the lower quartile were significantly higher for older individuals (odds ratio, 1.11 per year of age; 95% confidence interval, 1.08 to 1.20; P=0.004) and for the dialysis group compared with the control group (odds ratio, 2.7; 95% confidence interval, 1.13 to 7.51; P=0.05). Within the dialysis group, older age and lower lymphocyte count were associated with antibody response in the lower quartile (odds ratio, 1.22 per 1-year older; 95% confidence interval, 1.13 to 1.68; P=0.03 and odds ratio, 0.83 per 10-e3/µl-higher lymphocyte count; 95% confidence interval, 0.58 to 0.97; P=0.05). CONCLUSIONS: Although most patients on maintenance hemodialysis developed a substantial humoral response following the BNT162b2 vaccine, it was significantly lower than controls. Age was an important factor in the humoral response, regardless of chronic medical conditions.
Authors: Shuchi Anand; Maria E Montez-Rath; Jialin Han; Pablo Garcia; LinaCel Cadden; Patti Hunsader; Russell Kerschmann; Paul Beyer; Mary Dittrich; Geoffrey A Block; Scott D Boyd; Julie Parsonnet; Glenn M Chertow Journal: medRxiv Date: 2021-05-12
Authors: Jens Van Praet; Marijke Reynders; Dirk De Bacquer; Liesbeth Viaene; Melanie K Schoutteten; Rogier Caluwé; Peter Doubel; Line Heylen; Annelies V De Bel; Bruno Van Vlem; Deborah Steensels; An S De Vriese Journal: J Am Soc Nephrol Date: 2021-09-29 Impact factor: 10.121
Authors: David Cucchiari; Natalia Egri; Marta Bodro; Sabina Herrera; Jimena Del Risco-Zevallos; Joaquim Casals-Urquiza; Frederic Cofan; Asunción Moreno; Jordi Rovira; Elisenda Banon-Maneus; Maria J Ramirez-Bajo; Pedro Ventura-Aguiar; Anna Pérez-Olmos; Marta Garcia-Pascual; Mariona Pascal; Anna Vilella; Antoni Trilla; José Ríos; Eduard Palou; Manel Juan; Beatriu Bayés; Fritz Diekmann Journal: Am J Transplant Date: 2021-08-04 Impact factor: 9.369
Authors: Gian Luca Salvagno; Brandon M Henry; Giovanni di Piazza; Laura Pighi; Simone De Nitto; Damiano Bragantini; Gian Luca Gianfilippi; Giuseppe Lippi Journal: Diagnostics (Basel) Date: 2021-05-04
Authors: Edward J Carr; Andreas Kronbichler; Matthew Graham-Brown; Graham Abra; Christos Argyropoulos; Lorraine Harper; Edgar V Lerma; Rita S Suri; Joel Topf; Michelle Willicombe; Swapnil Hiremath Journal: Kidney Int Rep Date: 2021-07-06